ADCYAP1R1 and cancer: Relatively weak endogenous agonist selectivity and the impact of alternative splicing on observed agonist potency still prevent the efficient use of VPAC and PAC1 receptors as molecular targets in endocrine, metabolic, anti-inflammatory, and anti-cancer therapies [53].